Management of Hypertension

Introduction to Hypertension Management

Hypertension treatment guidelines are established by various organizations, including the American College of Cardiology and the American Heart Association, to provide evidence-based recommendations for the management of hypertension 1, 2, 3, 4

The initial dose of lisinopril is 2.5-5 mg once daily, with a target dose of 20-40 mg once daily, as recommended by the American College of Cardiology and the European Heart Journal 1, 2
High-dose lisinopril (32.5-35 mg daily) has shown significant benefits over low-dose (2.5-5 mg daily) in the ATLAS trial, with a 12% reduction in death or hospitalization, as reported by the European Heart Journal 2
The dose of lisinopril should be increased gradually every 1-2 weeks as tolerated, with a target dose of 20-40 mg once daily, according to the American College of Cardiology 1
The American College of Cardiology recommends a maximum dose of valsartan 320 mg daily, amlodipine 10 mg daily, and hydrochlorothiazide 25 mg daily when used in combination for hypertension treatment 5, 6
The target dose for valsartan in heart failure is 160 mg twice daily (320 mg total daily) 5, 6
Valsartan can be administered at doses of up to 320 mg/day in hypertension, with 160 mg being the optimal initial dose for most patients 6
The following medication dosages are recommended:

Medication	Initial Dose	Maximum Dose	Frequency
Amlodipine	2.5-5 mg	10 mg	Once daily
Losartan	25-50 mg	50-100 mg	Once or twice daily	[4]

When converting from olmesartan 20 mg to losartan, the equivalent dose is 50 mg of losartan once daily, as recommended by the American College of Cardiology 5
When switching from telmisartan 80 mg to losartan, start with losartan 100 mg daily to achieve comparable antihypertensive effect, and monitor blood pressure closely due to the difference in half-lives between the two medications 7, 8
When switching from lisinopril to losartan, the equivalent dose is 50 mg once daily, with potential titration to 100-150 mg daily as needed for optimal blood pressure control and cardiovascular outcomes, as recommended by the American College of Cardiology and the American Heart Association 9, 10

Follow-up evaluation of adherence and response to treatment should occur at monthly intervals until blood pressure control is achieved 11
Blood pressure, renal function, and electrolytes should be monitored 1-2 weeks after starting treatment and after each dose increase 5
The American Heart Association recommends monitoring every 3 months and then every 6 months 6
Check renal function and potassium levels within 1-2 weeks after switching medications, particularly in patients with pre-existing hypotension, hyponatremia, diabetes mellitus, renal impairment, or those taking potassium supplements, with a moderate strength of evidence 12, 1

Losartan is contraindicated in pregnancy and history of angioedema with ARBs, and should be used with caution in patients with severe bilateral renal artery stenosis or elevated potassium levels (>5.0 mEq/L) 4, 12, 13
ACE inhibitors like enalapril were shown to be the most effective agents for LVH regression in a meta-analysis, leading to a 13.3% reduction in left ventricular mass, with a high strength of evidence, but commonly cause dry cough (up to 20% of patients), while losartan and other ARBs rarely cause cough, making them suitable alternatives for patients who develop cough on ACE inhibitors 14, 1
In patients with renal impairment (GFR < 30 mL/min), lower doses of lisinopril are required, as suggested by the European Heart Journal 15
Many patients are undertreated with suboptimal doses of ACE inhibitors, and higher doses provide greater clinical benefits, as demonstrated in the ATLAS trial, according to the European Journal of Heart Failure 2, 16

The transition from IV nicardipine to oral losartan should occur when the patient has achieved stable blood pressure control for at least 24 hours and can safely tolerate oral medications, with the nicardipine infusion rate reduced by 25% every 2-4 hours, and close monitoring of blood pressure every 15-30 minutes during taper 17, 18
The combination of valsartan, amlodipine, and hydrochlorothiazide has been studied with maximum doses of 320 mg/day, 10 mg/day, and 25 mg/day, respectively 5, 6
The combination of valsartan 160 mg and hydrochlorothiazide 12.5 mg provides more sustained and homogeneous blood pressure control than amlodipine 10 mg in high-risk hypertensive patients 6
The triple combination has been shown to be more effective than the corresponding dual combinations 6